G-BAO Pharmaceutical

G-BAO Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on areas of high unmet medical need, including the central nervous system (CNS), chronic pain, and oncology. Its lead clinical candidate, GBA101, is a highly selective P2X3 receptor antagonist being developed for indications such as chronic cough and neuropathic pain. G-BAO leverages a management team with extensive experience from global pharmaceutical companies to advance its pipeline through rigorous R&D. The company's strategic focus remains on targeting validated biological pathways to develop best-in-class medicines. Since its inception, G-BAO has successfully transitioned from a discovery-focused startup to a clinical-stage entity with multiple active programs.